Some of the biggest names in medical oncology from Asia, Middle East and Africa gathered at Guardant Health AMEA’s new office on 27 March to share their views in an engaging panel discussion on transforming cancer care across all stages of the disease after an insightful sharing on the Future of Precision Oncology by Guardant Health’s Co-founder, AmirAli Talasaz. Guardant Health is the only precision oncology company with cutting edge diagnostics for advanced cancer, recurrence monitoring of cancer and early detection of cancer. These technologies across the continuum of cancer can help to bend mortality curves and cost curves of cancer globally.

Special thanks to Prof. Byoung Chul Cho from South Korea, Prof. James Chih-Hsin Yang from Taiwan, Prof. Nir Peled from Israel, Dr. Amit Rauthan and Dr. Nitesh Rohatgi from India, Dr. Marwan Al Akasheh from Jordan, Dr. Shaheenah Dawood from U.A.E., Dr. Herbert Loong from Hong Kong and Dr. Iain Tan from Singapore for being a part of our panel of experts at the event.

The event which marked Guardant Health AMEA’s 5^th year anniversary in Singapore since its inception in 2018 was well attended by medical oncologists, biopharmaceutical partners, screening center physicians, insurers, Singapore Cancer Society members and friends and well-wishers of the company.

Visit us at https://lnkd.in/gHNdYtQN to find out more about our comprehensive genomic profiling tests which can help guide treatment decisions for patients with cancer.

#guardanthealth #guardanthealthamea #futureofprecisiononcology #medicaloncologists #event #newoffice #cancercarecontinuum #nextgenerationsequencing #comprehensivegenomicprofiling #guardant360 #guardantreveal #liquidbiopsy #guardant360tissuenext #tissuebiopsy